Abstract
Comprehensive analysis of ferroptosis in Hepatocellular Carcinoma (HCC) and its relation to the tumor immune microenvironment are needed. Data included HCC in The Cancer Genome Atlas and International Cancer Genome Consortium. And two datasets from Gene Expression Omnibus (GEO) were used as the validation set. Based on the expression of ferroptosis-related genes, HCC patients were divided into two subtypes. Cluster 1 showed lower tumor grade, lower CTLA-4, and a more favorable prognosis than Cluster 2. Patients with higher SLC7A11 (50%) had a poorer prognosis in HCC. SLC7A11 is characterized by more NK CD56bright cells, less DC, and neuroactive ligand–receptor interaction and cytokine receptor interaction. Ferroptosis-related genes especially SLC7A11 might be a valuable prognostic factor in HCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
This is a secondary analysis of public online clinical data (TCGA-LIHC: https://portal.gdc.cancer.gov/; ICGC: https://dcc.icgc.org/projects/LIRI-JP; GEO: https://ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36376; https://ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62232).
Abbreviations
- HCC:
-
Hepatocellular carcinoma
References
Angeli JPF, Shah R, Pratt DA, Conrad M (2017) Ferroptosis inhibition: mechanisms and opportunities. Trends Pharmacol Sci 38(5):489–498. https://doi.org/10.1016/j.tips.2017.02.005
Chen Y, Fan Z, Hu S, Lu C, Xiang Y, Liao S (2022) Ferroptosis: a new strategy for cancer therapy. Front Oncol 12:830561. https://doi.org/10.3389/fonc.2022.830561
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14(2):135–146. https://doi.org/10.1038/nrc3670
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF (2017) Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66(3):545–551. https://doi.org/10.1016/j.jhep.2016.10.029
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Rd Welling TH, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502. https://doi.org/10.1016/s0140-6736(17)31046-2
Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242. https://doi.org/10.1111/j.1600-065X.2010.00923.x
Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD, Christofori G, Tang F (2021) YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 13(12):e14351
Gardner A, Ruffell B (2016) Dendritic cells and cancer immunity. Trends Immunol 37(12):855–865. https://doi.org/10.1016/j.it.2016.09.006
Greten TF, Sangro B (2017) Targets for immunotherapy of liver cancer. J Hepatol. https://doi.org/10.1016/j.jhep.2017.09.007
Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, Lee B (2021) M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials 278:121137. https://doi.org/10.1016/j.biomaterials.2021.121137
He G, Karin M (2011) NF-κB and STAT3: key players in liver inflammation and cancer. Cell Res 21(1):159–168. https://doi.org/10.1038/cr.2010.183
Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X (2020) Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest 130(4):1752–1766. https://doi.org/10.1172/jci124049
Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K, Zhang Q, Zhang X, Sheng H, Ju HQ, Cheng H, Wang F, Xu RH, Liu ZX (2020) Systematic analysis of the aberrances and functional implications of ferroptosis in cancer. iScience 23(7):101302. https://doi.org/10.1016/j.isci.2020.101302
Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF (2015) The yin and yang of evasion and immune activation in HCC. J Hepatol 62(6):1420–1429. https://doi.org/10.1016/j.jhep.2015.02.038
Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, Zanellato S, Mortara L, Gattorno M, Pistoia V, Malavasi F (2015) CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol 195(3):965–972. https://doi.org/10.4049/jimmunol.1500591
Oura K, Morishita A, Tani J, Masaki T (2021) Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. https://doi.org/10.3390/ijms22115801
Qi J, Kim JW, Zhou Z, Lim CW, Kim B (2020) Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. Am J Pathol 190(1):68–81. https://doi.org/10.1016/j.ajpath.2019.09.011
Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67. https://doi.org/10.1182/blood-2017-06-741033
Sato M, Kusumi R, Hamashima S, Kobayashi S, Sasaki S, Komiyama Y, Izumikawa T, Conrad M, Bannai S, Sato H (2018) The ferroptosis inducer erastin irreversibly inhibits system x(c)- and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells. Sci Rep 8(1):968. https://doi.org/10.1038/s41598-018-19213-4
Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM (2016) The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45(2):374–388. https://doi.org/10.1016/j.immuni.2016.07.009
Schwinghammer UA, Melkonyan MM, Hunanyan L, Tremmel R, Weiskirchen R, Borkham-Kamphorst E, Schaeffeler E, Seferyan T, Mikulits W, Yenkoyan K, Schwab M, Danielyan L (2020) α2-adrenergic receptor in liver fibrosis: implications for the adrenoblocker mesedin. Cells. https://doi.org/10.3390/cells9020456
Udumyan R, Montgomery S, Duberg AS, Fang F, Valdimarsdottir U, Ekbom A, Smedby KE, Fall K (2020) Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients. Scand J Gastroenterol 55(5):597–605. https://doi.org/10.1080/00365521.2020.1762919
Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380(15):1450–1462. https://doi.org/10.1056/NEJMra1713263
Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W (2019) CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569(7755):270–274. https://doi.org/10.1038/s41586-019-1170-y
Wang S, Chen S, Ying Y, Ma X, Shen H, Li J, Wang X, Lin Y, Liu B, Zheng X, Xie L (2021) Comprehensive analysis of ferroptosis regulators with regard to PD-L1 and immune infiltration in clear cell renal cell carcinoma. Front Cell Dev Biol 9:676142. https://doi.org/10.3389/fcell.2021.676142
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D (2016) Ferroptosis: process and function. Cell Death Differ 23(3):369–379. https://doi.org/10.1038/cdd.2015.158
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1–2):317–331. https://doi.org/10.1016/j.cell.2013.12.010
Yu J, Xia X, Dong Y, Gong Z, Li G, Chen GG, Lai PBS (2021) CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling. Theranostics 11(5):2123–2136. https://doi.org/10.7150/thno.49368
Zhang L, Huang Y, Ling J, Zhuo W, Yu Z, Luo Y, Zhu Y (2018) Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma. Future Oncol 14(10):927–936. https://doi.org/10.2217/fon-2017-0540
Zhu D, Wu S, Li Y, Zhang Y, Chen J, Ma J, Cao L, Lyu Z, Hou T (2022) Ferroptosis-related gene SLC1A5 is a novel prognostic biomarker and correlates with immune infiltrates in stomach adenocarcinoma. Cancer Cell Int 22(1):124. https://doi.org/10.1186/s12935-022-02544-8
Zongyi Y, Xiaowu L (2020) Immunotherapy for hepatocellular carcinoma. Cancer Lett 470:8–17. https://doi.org/10.1016/j.canlet.2019.12.002
Acknowledgements
Thanks for Yanjie Chen’s effort to enlighten the design.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
XW designed the study. JX and XW finished the analysis work. JX wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Ethical Approval
Not applicable.
Informed Consent
Not applicable.
Consent for Publication
All authors have consented for the publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Xu, J., Wu, X. & Wang, X. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma. Biochem Genet 61, 687–703 (2023). https://doi.org/10.1007/s10528-022-10279-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-022-10279-4